HomepageSHTDF • OTCMKTS
add
Sinopharm Group Co Ltd
Vorige slotkoers
$ 1,97
Jaar-range
$ 1,97 - $ 2,95
Beurswaarde
63,04 mld. HKD
Koers/winst
-
Dividendrendement
-
Primaire beurs
HKG
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(CNY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 147,46 mld. | -5,13% |
Bedrijfskosten | 6,38 mld. | -2,07% |
Netto inkomsten | 2,28 mld. | -9,16% |
Netto winstmarge | 1,55 | -4,32% |
Winst per aandeel | — | — |
EBITDA | 5,57 mld. | -12,42% |
Effectief belastingtarief | 21,74% | — |
Balans
Totale activa
Totale passiva
(CNY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 43,33 mld. | 26,05% |
Totale activa | 429,58 mld. | 2,85% |
Totale passiva | 307,15 mld. | 0,84% |
Totaal aandelenvermogen | 122,43 mld. | — |
Uitstaande aandelen | 3,12 mld. | — |
Koers-boekwaardeverhouding | 0,08 | — |
Rendement op activa | 2,96% | — |
Rendement op kapitaal | 5,84% | — |
Kasstroom
Nettomutatie in liquide middelen
(CNY) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 2,28 mld. | -9,16% |
Operationele kasstroom | 6,49 mld. | 346,39% |
Kasstroom uit beleggingen | -1,29 mld. | -269,35% |
Kasstroom uit financiering | -602,70 mln. | -425,16% |
Nettomutatie in liquide middelen | 4,59 mld. | 374,61% |
Vrije kasstroom | -22,56 mld. | 29,73% |
Over
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.
Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
Opgericht
2003
Website
Werknemers
113.635